Latest Insider Transactions at Athenex, Inc. (ATNX)
This section provides a real-time view of insider transactions for Athenex, Inc. (ATNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Athenex, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Athenex, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
58,762
+1.49%
|
$0
$0.19 P/Share
|
|
Nov 18
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,257
+5.44%
|
$0
$0.19 P/Share
|
|
Nov 18
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,578
+9.04%
|
$0
$0.19 P/Share
|
|
Nov 04
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
58,402
+1.51%
|
$0
$0.2 P/Share
|
|
Nov 04
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,103
+5.72%
|
$0
$0.2 P/Share
|
|
Nov 04
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,561
+9.87%
|
$0
$0.2 P/Share
|
|
Oct 21
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
62,637
+1.64%
|
$0
$0.18 P/Share
|
|
Oct 21
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,923
+6.47%
|
$0
$0.18 P/Share
|
|
Oct 21
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,747
+11.66%
|
$0
$0.18 P/Share
|
|
Oct 07
2022
|
Jinn Wu Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,284
+6.35%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
John Vierling Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,284
+33.32%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Benson Kwan Hung Tsang Director |
BUY
Grant, award, or other acquisition
|
Direct |
47,737
+32.24%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Robert J. Spiegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,453
+29.54%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Manson Fok Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,133
+1.49%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Stephanie A Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,717
+24.15%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,076
+10.31%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,340
+5.32%
|
$0
$0.24 P/Share
|
|
Oct 07
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
47,323
+1.26%
|
$0
$0.24 P/Share
|
|
Sep 23
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
47,303
+1.28%
|
$0
$0.24 P/Share
|
|
Sep 23
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,333
+5.62%
|
$0
$0.24 P/Share
|
|
Sep 23
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,075
+11.49%
|
$0
$0.24 P/Share
|
|
Sep 16
2022
|
Timothy De Vere Cook Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
548
-3.79%
|
$0
$0.41 P/Share
|
|
Sep 16
2022
|
Timothy De Vere Cook Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+13.46%
|
-
|
|
Sep 16
2022
|
Daniel Lang Pres Cell Therapy, VP Corp Dev |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-5.03%
|
$0
$0.41 P/Share
|
|
Sep 16
2022
|
Daniel Lang Pres Cell Therapy, VP Corp Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+12.7%
|
-
|
|
Sep 09
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,079
+8.12%
|
$0
$0.46 P/Share
|
|
Sep 09
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,572
+3.18%
|
$0
$0.46 P/Share
|
|
Sep 09
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
24,596
+0.68%
|
$0
$0.46 P/Share
|
|
Aug 26
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+8.66%
|
$0
$0.47 P/Share
|
|
Aug 26
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,346
+3.22%
|
$0
$0.47 P/Share
|
|
Aug 26
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
24,071
+0.67%
|
$0
$0.47 P/Share
|
|
Aug 22
2022
|
Jinn Wu Director |
BUY
Open market or private purchase
|
Direct |
10,000
+2.02%
|
$0
$0.42 P/Share
|
|
Aug 19
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Open market or private purchase
|
Direct |
20,000
+0.56%
|
$0
$0.45 P/Share
|
|
Aug 12
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
961
+8.7%
|
$0
$0.52 P/Share
|
|
Aug 12
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
21,923
+0.62%
|
$0
$0.52 P/Share
|
|
Aug 12
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,423
+3.04%
|
$0
$0.52 P/Share
|
|
Aug 03
2022
|
John Vierling Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+17.51%
|
-
|
|
Aug 03
2022
|
Benson Kwan Hung Tsang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+15.98%
|
-
|
|
Aug 03
2022
|
Robert J. Spiegel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+33.66%
|
-
|
|
Aug 03
2022
|
Jordan Kanfer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+30.51%
|
-
|
|
Aug 03
2022
|
Manson Fok Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+0.31%
|
-
|
|
Aug 03
2022
|
Stephanie A Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+17.17%
|
-
|
|
Aug 03
2022
|
Jinn Wu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+1.56%
|
-
|
|
Aug 03
2022
|
Jeffrey Yordon Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,663
-1.47%
|
$0
$0.58 P/Share
|
|
Aug 03
2022
|
Jeffrey Yordon Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+4.77%
|
-
|
|
Aug 03
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
9,132
-0.26%
|
$0
$0.58 P/Share
|
|
Aug 03
2022
|
Johnson Yiu Nam Lau CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+1.05%
|
-
|
|
Aug 03
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,262
-1.44%
|
$0
$0.58 P/Share
|
|
Aug 03
2022
|
Rudolf Kwan EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+5.59%
|
-
|
|
Jul 29
2022
|
Timothy De Vere Cook Officer |
BUY
Grant, award, or other acquisition
|
Direct |
986
+9.76%
|
$0
$0.51 P/Share
|